Navigation Links
AstraZeneca Announces Top-line Phase III Results from Naloxegol Pivotal Trials In Patients With Opioid-Induced Constipation
Date:11/12/2012

Meeting and the American Academy of Pain Management Annual Meeting. Naloxegol was developed using Nektar's oral small molecule polymer conjugate technology.

About Opioid-Induced Constipation 
Opioids attach to specific proteins called opioid receptors. When the opioids attach to certain opioid receptors in the gastrointestinal tract, constipation may occur. Opioid-induced constipation (OIC) is a result of decreased fluid absorption and lower gastrointestinal motility due to opioid receptor binding in the gastrointestinal tract.

Globally, approximately 40–50% (28-35 million) patients taking opioids for long-term pain develop constipation. About 40–50% (11-18 million) of those OIC sufferers achieve the desired treatment outcomes with current options that include over-the-counter and prescription laxatives.

About Nektar
Nektar Therapeutics (NASDAQ: NKTR) is a clinical-stage biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugate technology platforms. Nektar has a robust R&D pipeline of therapeutic candidates in oncology, pain and other areas. The company is headquartered in San Francisco, California, with additional R&D operations in Huntsville, Alabama and Hyderabad, India. Further information about Nektar and its drug development programs and capabilities may be found online at www.nektar.com

About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
2. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
3. AstraZeneca and Rigel Sign Worldwide License Agreement for a Potential New Treatment for Chronic Asthma
4. Covington Advises AstraZeneca in $1.26 Billion Acquisition of Ardea Biosciences
5. China Cord Blood Corporation Announces Completion of Strategic Partnership with Cordlife Group Limited
6. Apexigen Announces Initiation of Clinical Trials By Its Partner, Simcere Pharmaceutical Group
7. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
8. Boston Childrens Hospital announces international genomics competition winner
9. Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference
10. OncoGenex Announces Completion Of Patient Enrollment In Custirsen Phase 3 "SYNERGY" Study
11. AMRI Announces Third Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 2015 MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) ... Company,s lead antibody, HuMab 5B1, will be garnering major ... the upcoming World Molecular Imaging Congress (WMIC) being held ... Researchers from the Department of Radiology at Memorial Sloan ... use of MabVax,s lead antibody as a PET imaging ...
(Date:8/31/2015)... DUBLIN , Aug. 31, 2015 Research ... of the "Middle East & Africa Biomedical Sensors ... to their offering. The ... is estimated at $0.84 billion by 2018 at a ... The near future will bring Biomedical sensors that are ...
(Date:8/31/2015)... -- US-Australian drug discovery company, Novogen Limited (ASX: NRT; ... scientific review has identified high value opportunities for ... patient need. Novogen is moving as quickly as ... entering into Phase 1 clinical trials with our ... Officer, Iain Ross , said that following ...
(Date:8/31/2015)... -- Trimb Healthcare AB ("Trimb") today announced that it ... ("YouMedical"), a Dutch OTC company with operations in key ... EUR 16 million, with solid growth and leading brands ... to build a leading international OTC company, and this ... gives us a stronger North European OTC platform, from ...
Breaking Biology Technology:MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 2MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 3MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 4Middle East & Africa Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts to 2020 2Novogen Announces The Outcome Of A Comprehensive Science Review 2Novogen Announces The Outcome Of A Comprehensive Science Review 3Novogen Announces The Outcome Of A Comprehensive Science Review 4Novogen Announces The Outcome Of A Comprehensive Science Review 5Novogen Announces The Outcome Of A Comprehensive Science Review 6
... . - GE Healthcare and the Vancouver ... million agreement under which the authority would purchase 48 new ... advanced ultrasound technologies and establish new clinical workflow and administrative ... board, said the agreement will result in more precise diagnosis ...
... a series of articles on developing start-up companies in the ... business taxes. , , Madison, Wis. ... begin hiring workers. As discussed in the previous article, you ... Security and Medicare taxes, and unemployment taxes ...
... has added so much complexity to information technology systems ... ,That according to John Swainson, president and CEO of ... address at the 2007 Fusion CEO-CIO Symposium . ... relationship between business and information technology. , ,That relationship ...
Cached Biology Technology:Early Stage 7, Part I: Just what is an employee? 2Early Stage 7, Part I: Just what is an employee? 3Early Stage 7, Part I: Just what is an employee? 4Early Stage 7, Part I: Just what is an employee? 5Fusion 2007: CA chief says IT complexity raises risk 2Fusion 2007: CA chief says IT complexity raises risk 3
(Date:8/4/2015)... ) today reported financial and operating results for the second quarter ... quarter contract revenue of $ 85.2 million, a ... of 26 % , Second quarter adjusted ... royalties in the current quarter , Operating cash ... to present another strong financial quarter, with all our divisions achieving ...
(Date:7/31/2015)... -- Den 10. internationale konference om Genomik (ICG-10, ... 25. oktober i Shenzhen , Kina. ... år. Siden starten i 2006 er ICB blevet en ... er en af de mest dynamiske, entusiastiske og sjove ... gennembrud og fremskridt inden for ,omik,-forskning, som yderligere vil ...
(Date:7/31/2015)... SHENZHEN, China , 31 de julho de 2015 ... Genômica (ICG-10, www.icg-10.org ) será realizada pela BGI de ... China . A conferência está ... inauguração em 2006, a ICG se tornou uma das ... e um dos encontros científicos mais dinâmicos, entusiastas e ...
Breaking Biology News(10 mins):AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
... depends on the nutritional value and yield of staple food ... an increase in toxic compounds, a decrease in protein content ... 2 and drought conditions. The research, to ... at the Society for Experimental Biology Annual Meeting in Glasgow, ...
... of survival is now better understood. For the first ... Berkeley National Laboratory observed the chemical changes in individual ... kill them. The team tracked the chemical changes ... normally can only exist in an oxygen-free environment. They ...
... Paths" is a response to confusion and uncertainty on ... and electricity -- as a prominent factor in meeting ... joining forces to seek resolution of issues related to ... opportunities to integrate biomass production with food crops and ...
Cached Biology News:Scientists track chemical changes in cells as they endure extreme conditions 2Scientists track chemical changes in cells as they endure extreme conditions 3Sustainable bioenergy project has global launch 2
... developed specifically for pulsed field separations of DNA larger than 2, ... megabase pairs. This agarose has the highest gel ... ... Chromosomal Grade, ...
... this enzyme exists predominantly as XDH which ... a critical plasma antioxidant. During ischemia, ... radical producing XO by oxidation of essential ... cleavage of the amino-terminus. AO has ...
Rabbit Anti-Human Janus Kinase 2 (JAK2 Polyclonal Antibody Family: Protein Kinase Sub-Family: TYK2/JAK Applications: ELISA, Western Blot...
... 2 (VMAT2). An antibody made to the ... at ~55 kDa in postnuclear supernatants of ... wild type cells (2). Some additional bands, ... also detected and remain unaffected by the ...
Biology Products: